KLONOPIN RAPIDLY DISINTEGRATING
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLONOPIN Rapidly Disintegrating is an orally disintegrating tablet formulation of clonazepam, a benzodiazepine with anxiolytic, anticonvulsant, and muscle-relaxant properties. The rapidly disintegrating formulation enhances patient convenience and compliance by eliminating the need for water during administration. It is indicated for anxiety disorders, seizure disorders, and panic disorder.
LOE Approaching
LOE-approaching lifecycle with moderate competitive pressure (30/100) signals transitional career dynamics; brand teams are increasingly focused on lifecycle management and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KLONOPIN Rapidly Disintegrating offers limited career growth due to its LOE-approaching lifecycle and minimal linked job opportunities; career value lies in managing market share defense, generic transition strategy, and cost-containment initiatives. This role suits professionals seeking stability in mature markets rather than growth-stage innovation experience.
Brand Manager
Worked on KLONOPIN RAPIDLY DISINTEGRATING at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.